**INTRODUCTION**

Fahr syndrome is defined by the presence of calcifications of the basal ganglia bilateral and symmetrical, particularly affecting patients with dysparathyroidism, more rarely pseudohypoparathyroidism (PHP).\(^1\)

The disease was first described and named by Fuller Albright and colleagues in 1942.\(^2\) It is a heterogeneous group of disorders characterized by hypocalcemia, hyperphosphatemia, increased serum concentration of parathyroid hormone (PTH), and insensitivity to the biologic activity of PTH. One of its most common types is PHP-1a. In this report, we present a familial PHP-1a and a novel mutation of the GNAS gene.

The exact prevalence of PHP is unknown\(^5\) because the investigators did not confirm the clinical diagnosis of PHP by a molecular analysis for most of the patients.

Herein, we report a case of Fahr syndrome which allowed the diagnosis of very rare GNAS mutation in familial pseudohypoparathyroidism type 1a.

**CASE PRESENTATION**

A 31-year-old man was born at full term. There was a distant familial consanguinity. Followed since the age of 15 for recurrent convulsive seizures (initial etiological investigation was negative specifically the serum calcium level was strictly normal), put on anti-epileptic treatment. Recently, the patient has reported memory disorders, a brain magnetic resonance imaging (MRI) has been carried out and revealed the presence of basal ganglia calcification. The patient was referred to our department for further explorations.

At admission, he was conscious with Glasgow Coma Scale of 15 points, afebrile, and had stable vital signs. He...
had positive Chvostek and Trousseau signs without tetany. The neurologic examination revealed no focal signs.

Clinical examination showed short stature (height 1.39 m <5th percentile), weight of 43 kg (<5th percentile) with body mass index of 22.7 kg/m², round face, dental hypoplasia, diastema, short neck, brachymetacarpy, brachymetatarsia, and subcutaneous ectopic ossifications (Figures 1, 2 and 3). Electrocardiogram revealed a prolonged QTc interval (0.47 sec). The ophthalmologic examination showed a bilateral subcapsular cataract.

Laboratory findings showed severe hypocalcemia, with albumin correction, 1.15 mmol/L (normal range 2.2–2.6 mmol/L), hyperphosphatemia 2.76 mmol/L (normal range 0.87–1.45 mmol/L), while the serum PTH level was 320 pg/ml (normal range 15–65 pg/ml) with low calcium in the 24-h urine collection 26.6 mg/24 h (normal range 100–300 mg/24 h), normal renal function, normal vitamin D (28 ng/ml, normal range 20–40 ng/ml), and normal serum magnesium 0.82 mmol/L (normal range 0.7–1.05 mmol/L).

Thyroid function showed elevated thyroid-stimulating hormone (TSH) 8.62 uIU/ml (normal range 0.27–4.2 uIU/ml), with normal free thyroxine of 16.51 pmol/L (normal range 12–22 pmol/L). He was negative for anti-thyroid peroxidase antibody (TPOA), and thyroid ultrasonography was normal. Basal growth hormone (GH) was <0.03 ng/ml which could be probably explained by the resistance to the action of GHRH (GHRH was not performed). Cortisol, follicle-stimulating hormone (FSH), and serum testosterone levels were within the normal range.

Depending on the history, clinical manifestations, and initial blood investigation, the diagnosis of PHP type 1a was considered. After explaining to the patient, the implications of the diagnosis, we were able to obtain consent to further investigation.

The family investigation revealed the presence of the same clinical and biological presentation in his sister and his younger brother and the discovery of asymptomatic hypocalcemia in the mother. His father was healthy and normal (Table 1).

A mutation analysis on the GNAS gene was performed for the patient and his family (parents, brother, and sister). Genomic DNA was isolated from peripheral blood. GNAS exons and intron/exon boundaries were sequenced (reference sequence NM_000516) with identification of the very rare frameshift mutation c.860_861del p (Val287 Aspfs*12) in heterozygosity, in the location 20q13.2- q13.32 exon 11 of GNAS gene which is absent from international databases (GnomAD). This mutation is detected in our index case, in his mother, sister, and brother. This variation was inherited from his mother. The diagnosis of PHP-1a with AHO and PTH, TSH, and probably GHRH resistance was retained.

The patient began intravenous infusion with ten percent calcium gluconate and 0.5 μg/day of 1α(OH)D₃. The clinical conditions rapidly improved, and the values of calcium gradually increased to allow, on the third day of hospitalization, a transition to oral supplementation. We started treatment with 3 g/day of calcium lactate hydrate and 1 μg/day of 1α(OH)D₃. During follow-ups, his calcemia levels

![FIGURE 1](image1.png)

Photographs of our index case: short stature, short neck, mandibular propulsion

![FIGURE 2](image2.png)

Brachydactyly. (A) Brachydactyly of the hands. Shortened fourth digits in both hands are very remarkable. (B) Radiograph of both hands: brachydactyly due to shortening of metacarpals
were normal and PTH reduced to 98 pg/ml. He had no further seizures. Simultaneous therapeutic management of other members of his family was carried out.

3 | DISCUSSION

We report a case of Fahr syndrome discovered in adulthood at the age of 31 during memory disorders and hypocalcemic convulsions progressing from childhood which allowed the diagnosis of familial PHP type 1a.

The diagnosis of PHP-1a was retained in accordance with the recommendations of the recently published first consensus statement on the diagnosis and management of PHP-related disorders. The diagnosis should be based on clinical and biochemical characteristics, which will vary according to the age of the patient. The diagnosis of AHO should be based on the presence of major criteria (brachydactyly due to premature fusion of the epiphyses and short stature by adulthood) and additional criteria (stocky build, round facies, and ectopic ossifications).

![Figure 3](image)

**FIGURE 3** Shortening of all toes (particularly the fourth)

**TABLE 1** Laboratory findings

|          | Index case | Brother | Sister | Mother | Father | Normal range |
|----------|------------|---------|--------|--------|--------|--------------|
| Calcium  | 1.15       | 1.78    | 1.98   | 2      | 2.48   | 2.2–2.6      |
| Phosphatemia | 2.76    | 1.94    | 1.62   | 1.74   | 0.92   | 0.87–1.45    |
| Parathyroid Hormone (pg/ml) | 320 | 467 | 280 | 442 | 54 | 15–65 |
| Magnesium | 0.82       | 0.81    | 0.86   | 0.81   | 0.87   | 0.7–1.05     |
| Creatinine | 64 | 76.9 | 62 | 70 | 72 | 55–115      |
| 25-OH-Vitamin D (ng/ml) | 28 | 30 | 27 | 26 | 29 | 20–40       |
| TSH (mU/ml) | 8.62 | 6.68 | 7.24 | 4.1 | - | 0.27–4.2 |
| FT4 (pmol/L) | 16.82 | 14.22 | 15.61 | 17.26 | - | 12–22 |
| GH (ng/ml) | <0.03 | <0.03 | <0.03 | 4.2 | - | 0.09–6.29 |
| FSH (mIU/ml) | 4.63 | 9.26 | 8.2 | - | - | 2–15 |
| Testosterone (ng/ml) | 5.2 | 8.12 | - | - | - | 2.8–8 |
| Estradiol (pg/ml) | - | - | 54.06 | - | - | 12.5–166 |

Obesity, dental manifestations, and cognitive impairment are present in a subgroup of patients.6

In our case, the principal manifestation was seizure and memory disorders resulted from Fahr syndrome which is a rare neurodegenerative disease characterized by bilateral basal ganglia calcification. Tetany and epilepsy were reported to be the most common symptoms in PHP patients. The prevalence of epilepsy was 47.1, and 94.6% for intracranial calcification with a positive correlation with seizures in a Chinese cohort of PHP.7 It was common in PHP patients, nevertheless the symptoms of the former disease usually occur between the fourth and sixth decade of life.8

In patients with PHP-1a, resistance to PTH is usually absent at birth and evolves over time (from the neonatal period to 22 years); the first biochemical abnormalities to appear are increased serum PTH and phosphorous levels, whereas hypocalcemia develops gradually 4–5 years later8 which explains the normality of serum calcium level during the initial etiological investigation of our patient at the age of 15 years.

Other associated endocrine features that support the diagnosis are as follows: early-onset hypothyroidism due to TSH resistance, which is the most common associated endocrine alteration, being present in nearly 100% of PHP-1a patients; hypogonadism (due to FSH and LH resistance); and GH deficiency (due to GHRH resistance).10 In our case, PTH, TSH, and probably GHRH resistance were found at the same time, which induced electrolytes disturbance, hypothyroidism. GH deficiency partially explains the final height deficit in patients with PHP-1a, with mean heights of 155 cm in men.11 In our case, the final height of the patient was 139 cm.

Genetically, PHP type 1a is due to a heterozygous loss of function of the alpha subunit of a G protein (Gsα), due to a GNAS mutation on the maternal allele of the chromosome 20q13.3, with autosomal dominant inheritance.12 This
intracellular protein is responsible for the production of cyclic AMP (cAMP) in response to PTH, and the reduced G protein activity is the molecular basis for hormone resistance in this disorder. The phenotype is most likely explained by the fact that some tissues (thyroid, pituitary, renal proximal tubules, and gonads) express Gsα predominantly from the maternal allele, while the paternal is silenced through yet unknown mechanisms. In this case, a novel heterozygous frameshift mutation, NM_000516 (GNAS): c.860_861del p.(Val287Aspfs*12), in exon 11 of the GNAS gene was identified for PHP-1a diagnosis. This very rare variant (absent GnomAD) was also detected in the brother, the sister, and the mother, thus confirming its maternal transmission in the autosomal dominant mode.

4 CONCLUSION

Our case is about a PHP-1a with a very rare frameshift mutation in GNAS gene in a patient presenting with characteristics of AHO, as well as TSH and GH resistance. There are over 340 reported GNAS mutations leading to PHP type 1a, and the identification of the responsible mutation in the index case is useful for screening other family members avoiding late diagnosis. The mutation in our case has not been reported in literature and adds to the spectrum of genetic mutations related to PHP.

AUTHOR CONTRIBUTION

Dayssem Khelifi conceived, analyzed, and drafted the manuscript. Wided Debbabi contributed to drafting and critical revision of the manuscript. Issam Kharrat and Slim Samet analyzed the case report.

ACKNOWLEDGEMENTS

The authors thank Dr Bruno Francou and the entire staff of genetics, pharmacogenetics, and hormonology at the Kremlin Bicetre Hospital for their contribution to the molecular analysis.

CONFLICTS OF INTEREST

The authors declare no conflicts of interest.

DATA AVAILABILITY STATEMENT

No data were available.

ETHICAL APPROVAL

Ethical approval for this case report was not required.

CONSENT

Written informed consent for publication of this case report was obtained from the patient.

ORCID

Wided Debbabi  https://orcid.org/0000-0002-1689-1771
Dayssem Khelifi  https://orcid.org/0000-0002-9097-7725

REFERENCES

1. Nassar K, Janani S. Fahr’s syndrome discovered at adulthood revealing the pseudohypoparathyroidism. Open J Rheumatol Autoimmune Dis. 2019;9:129-133.
2. Albright F, Burnett CH, Smith PH, Parson W. Pseudohypoparathyroidism—An example of ‘Seabright-Bantam syndrome’. Endocrinology. 1942;30:922-932.
3. Lu D, Dong A, Zhang J, et al. A novel GNAS mutation in pseudohypoparathyroidism type 1a in a Chinese man presented with recurrent seizure: a case report. BMC Endocr Disord. 2021;21:12.
4. Thiele S, de Sanctis L, Werner R, et al. Functional characterization of GNAS mutations found in patients with pseudohypoparathyroidism type 1c defines a new subgroup of pseudohypoparathyroidism affecting selectively Gsα-receptor interaction. Hum Mutat. 2011;32:653-660.
5. Yakoreva M, Kahre T, Zordania R, et al. A retrospective analysis of the prevalence of imprinting disorders in Estonia from 1998 to 2016. Eur J Human Genet. 2019;27(11):1649-1658.
6. Mantovani G, Bastepe M, Monk D, et al. Diagnosis and management of pseudohypoparathyroidism and related disorders: first international consensus statement. Nat Rev Endocrinol. 2018;14:476-500.
7. Chu X, Zhu Y, Wang O, et al. Clinical and genetic characteristics of pseudohypoparathyroidism in the Chinese population. Clin Endocrinol. 2018;88(2):285-291.
8. Shoback DM, Bilezikian JP, Costa AG, et al. Presentation of hypoparathyroidism: etiologies and clinical features. J Clin Endocrinol Metab. 2016;101(6):2300-2312.
9. Del Monte P, Cuttica CM, Marugo A, et al. unrecognized pseudohypoparathyroidism type 1A as a cause of hypocalcemia and seizures in a 64-year-old woman. Case Rep Endocrinol. 2019;2019:1-5. doi:10.1155/2019/8456239
10. Germain-Lee EL. Management of pseudohypoparathyroidism. Curr Opin Pediatr. 2019;31(4):537-549.
11. Long DN, McGuire S, Levine M, et al. Body mass index differences in pseudohypoparathyroidism type 1a versus pseudopseudohypoparathyroidism may implicate paternal imprinting of Gα(s) in the development of human obesity. J Clin Endocrinol Metab. 2007;92:1073-1079.
12. Tafaj O, Jüppner H. Pseudohypoparathyroidism: one gene, several syndromes. J Endocrinol Invest. 2017;40(4):347-356.
13. Moutinho A, Carvalho R, Ferreira Reis R, Tavares S. Identification of a novel mutation in a family with pseudohypoparathyroidism type 1a. Case Rep Endocrinol. 2018;2018:7813591.

How to cite this article: Debbabi W, Khelifi D, Kharrat I, Samet S. Fahr syndrome discovered in adulthood revealing a rare GNAS mutation in pseudohypoparathyroidism type 1a in a Tunisian family. Clin Case Rep. 2022;10:e05849. doi:10.1002/ccr3.5849